Since LCK is a druggable enzyme, we focused on this non-receptor tyrosine kinase to more closely investigate its biological role and target potential in the context of oral cancer cell migration, invasion and metastasis. This evidence concerns the gene NTRK1 and lip and oral cavity carcinoma.